Smileyscope – a global pioneer in immersive digital therapeutics – recently announced the successful closing of its seed prime round. The funding round included investments from Breakthrough Victoria, Ten13, Alice Anderson Fund and MedAngels. This funding round will enable Smileyscope to grow its clinical-stage pipeline, and rapidly expand across the health systems in the United States and Australia.
During common pediatric procedures, Smileyscope’s flagship product was designed to reduce pain and anxiety. And by using their patented therapy software, known as Procedural Choreography, Smileyscope replaces negative real-world stimuli with positive virtual stimuli, reducing procedural pain and anxiety. The largest virtual reality procedural clinical trials to date shows that their flagship product reduces needle pain and stress by 60% and 40%, respectively.1
Smileyscope was founded by two physicians: Dr. Evelyn Chan, a pediatric doctor and Rhodes Scholar, and Dr. Paul Leong, an adult pulmonologist and sleep specialist. And their technology has been adopted internationally for pain management in the Infusion Therapy Standards of Practice, and has transformed over 100,000 clinical experiences globally.
Smileyscope has been adopted in 100% of Australian Children’s Hospitals, and it is operationally profitable in Australia. And Smileyscope is rapidly expanding across leading Children’s Hospitals throughout the US, including Children’s Hospital of Orange County, Boston Children’s, Nicklaus Children’s, and numerous other Best Children’s Hospitals ranked in the U.S. News & World Report’s 2022-23.
KEY QUOTES:
“We invest in innovation for impact and Smileyscope’s virtual reality headset is a powerful example of how technology can make a real difference in people’s lives.”
- Grant Dooley, CEO of Breakthrough Victoria
“This investment will allow us to further unlock market opportunities internationally, resulting in more patients benefitting from Smileyscope’s revolutionary technology.”
- Dr. Evelyn Chan, co-founder and CEO of Smileyscope
“Our vision is to bring comprehensive digital therapies directly to the bedside, aimed at treating procedural pain and anxiety while reducing the costs of healthcare,” said Dr. Paul Leong, co-founder and Chief Medical Officer of Smileyscope. “This latest financing recognizes the strides we’ve made in building a platform that will ultimately be a standard tool for all providers.”
- Dr. Leong
